Silence Therap 
Welcome,         Profile    Billing    Logout  
 3 Products   0 Diseases  3 Products   1 Trial   139 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
divesiran (SLN124) / Silence Therap
SANRECO, NCT05499013: Study to Assess SLN124 in Patients With Polycythemia Vera

Recruiting
1/2
65
Europe, US, RoW
SLN124, Placebo
Silence Therapeutics plc
Polycythemia Vera
12/24
06/25
NCT04559971: A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

Completed
1
24
Europe
SLN124, Placebo
Silence Therapeutics plc
Healthy Volunteers
03/21
03/21
GEMINI II, NCT04718844: A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

Completed
1
44
Europe, RoW
SLN124, Placebo
Silence Therapeutics plc
Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome
05/23
05/23
zerlasiran (SLN360) / Silence Therap
NCT05537571 / 2022-001876-32: Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Completed
2
180
Europe, RoW
SLN360, Zerlasiran, Placebo
Silence Therapeutics plc
Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a)
01/24
07/24
NCT04606602: Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

Completed
1
70
Europe, US, RoW
SLN360, Placebo
Silence Therapeutics plc, Medpace, Inc.
Hyperlipidemias, Dyslipidemias, Elevated Lp(a)
08/23
08/23
SLN501 / Silence Therap, Mallinckrodt
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
divesiran (SLN124) / Silence Therap
SANRECO, NCT05499013: Study to Assess SLN124 in Patients With Polycythemia Vera

Recruiting
1/2
65
Europe, US, RoW
SLN124, Placebo
Silence Therapeutics plc
Polycythemia Vera
12/24
06/25
NCT04559971: A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

Completed
1
24
Europe
SLN124, Placebo
Silence Therapeutics plc
Healthy Volunteers
03/21
03/21
GEMINI II, NCT04718844: A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

Completed
1
44
Europe, RoW
SLN124, Placebo
Silence Therapeutics plc
Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome
05/23
05/23
zerlasiran (SLN360) / Silence Therap
NCT05537571 / 2022-001876-32: Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Completed
2
180
Europe, RoW
SLN360, Zerlasiran, Placebo
Silence Therapeutics plc
Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a)
01/24
07/24
NCT04606602: Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

Completed
1
70
Europe, US, RoW
SLN360, Placebo
Silence Therapeutics plc, Medpace, Inc.
Hyperlipidemias, Dyslipidemias, Elevated Lp(a)
08/23
08/23
SLN501 / Silence Therap, Mallinckrodt
No trials found

Download Options